Shiro Akinaga

8.3k total citations · 1 hit paper
122 papers, 6.6k citations indexed

About

Shiro Akinaga is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Shiro Akinaga has authored 122 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Molecular Biology, 46 papers in Oncology and 23 papers in Immunology. Recurrent topics in Shiro Akinaga's work include Heat shock proteins research (19 papers), Cancer therapeutics and mechanisms (14 papers) and Microtubule and mitosis dynamics (13 papers). Shiro Akinaga is often cited by papers focused on Heat shock proteins research (19 papers), Cancer therapeutics and mechanisms (14 papers) and Microtubule and mitosis dynamics (13 papers). Shiro Akinaga collaborates with scholars based in Japan, United States and Singapore. Shiro Akinaga's co-authors include Masami Okabe, Shiro Soga, Yukimasa Shiotsu, Tadakazu Akiyama, Katsushige Gomi, Ryuzo Ueda, Takashi Ishida, Tatsuya Tamaoki, Hiroshi Inagaki and Leonard Μ. Neckers and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Shiro Akinaga

121 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study

2012 478 citations Takashi Ishida, Hiroshi Inagaki et al. profile →

Peers

Countries citing papers authored by Shiro Akinaga

Since Specialization

Citations

This map shows the geographic impact of Shiro Akinaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiro Akinaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiro Akinaga more than expected).

Fields of papers citing papers by Shiro Akinaga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiro Akinaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiro Akinaga. The network helps show where Shiro Akinaga may publish in the future.

Co-authorship network of co-authors of Shiro Akinaga

This figure shows the co-authorship network connecting the top 25 collaborators of Shiro Akinaga. A scholar is included among the top collaborators of Shiro Akinaga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiro Akinaga. Shiro Akinaga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity 2016 ·Cancer Science ·Gary K. Schwartz, Mark A. Dickson, Patricia LoRusso, Edward A. Sausville, (unknown), Yasuo Watanabe, (unknown), Daisuke Nakashima, Shiro Akinaga	17
2	A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models 2015 ·Molecular Cancer Therapeutics ·Xiang S. Ye, Fan Li, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shiro Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory P. Donoho, Farhana F. Merzoug, Heng Li, Amit Aggarwal, Kerry Blanchard, Eric H. Westin	29
3	A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study) 2015 ·Annals of Oncology ·Hiroshige Yoshioka, K. Azuma, Nobuyuki Yamamoto, Toshiaki Takahashi, Makoto Nishio, Nobuyuki Katakami, Myung‐Ju Ahn, T. Hirashima, Makoto Maemondo, (unknown), Mami Kurosaki, Shiro Akinaga, K. Park, C.-M. Tsai, Tomohide Tamura, Tetsuya Mitsudomi, Kazuhiko Nakagawa	89
4	Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors 2013 ·Cancer Science ·Masashi Niwakawa, Raizo Yamaguchi, Yusuke Onozawa, Hirofumi Yasui, Keisei Taku, Tateaki Naito, Shiro Akinaga, Narikazu Boku, Nobuyuki Yamamoto	10
5	Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma 2013 ·Cancer Science ·Takashi Ishida, Asahi Ito, Fumihiko Sato, Shigeru Kusumoto, Shinsuke Iida, Hiroshi Inagaki, Akimichi Morita, Shiro Akinaga, Ryuzo Ueda	99
6	Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas 2012 ·Current Hematologic Malignancy Reports ·Kensei Tobinai, Takeshi Takahashi, Shiro Akinaga	33
7	New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells 2010 ·Clinical Cancer Research ·Takayuki Nakashima, Toshihiko Ishii, (unknown), Toshihiro Seike, Hiroshi Nakagawa, Yutaka Kanda, Shiro Akinaga, Shiro Soga, Yukimasa Shiotsu	69
8	Engineered therapeutic antibodies with improved effector functions 2009 ·Cancer Science ·Tsuguo Kubota, Rinpei Niwa, Mitsuo Satoh, Shiro Akinaga, Kenya Shitara, Nobuo Hanai	117
9	Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Hiroshi Ishida, (unknown), (unknown), (unknown), Yoshinori Yamashita, Jiro Kajita, Eiichi Fuse, Hitoshi Kiyoi, Tomoki Naoe, Shiro Akinaga, Yukimasa Shiotsu, Hitoshi Arai	9
10	Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients 2008 ·The Journal of Steroid Biochemistry and Molecular Biology ·Masayo Suzuki, Hiroyuki Ishida, Yukimasa Shiotsu, Taisuke Nakata, Shiro Akinaga, Shigemitsu Takashima, Toshiaki Utsumi, Toshiaki Saeki, Nobuhiro Harada	29
11	Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes 2006 ·Journal of Controlled Release ·Masahiro Yamauchi, (unknown), Etsuko Saito, (unknown), (unknown), Yasuki Kato, Takaaki Uochi, Shiro Akinaga, (unknown)	12
12	Development of Radicicol Analogues 2003 ·Current Cancer Drug Targets ·Shiro Soga, Yukimasa Shiotsu, Shiro Akinaga, Sreenath V. Sharma	100
13	Halohydrin and Oxime Derivatives of Radicicol: Synthesis and Antitumor Activities 2002 ·Bioorganic & Medicinal Chemistry ·Tsutomu Agatsuma, Harumi Ogawa, (unknown), Akira Asai, Yoshinori Yamashita, Tamio Mizukami, Shiro Akinaga, Yutaka Saitoh	87
14	A Radicicol Derivative, KF58333, Inhibits Expression of Hypoxia‐inducible Factor‐1α and Vascular Endothelial Growth Factor, Angiogenesis and Growth of Human Breast Cancer Xenografts 2001 ·Japanese Journal of Cancer Research ·Junichi Kurebayashi, (unknown), Masafumi Kurosumi, Shiro Soga, Shiro Akinaga, Hiroshi Sonoo	48
15	Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis 2000 ·British Journal of Cancer ·Hisashi Shinohara, (unknown), Kiyotsugu Yoshikawa, Shujiro Yazumi, (unknown), Yoshio Yamaoka, Takuo Mizukami, Tomonori Yoshida, Shiro Akinaga, T Tamaoki, Hirotoshi Motoda, William F. Benedict, Rei Takahashi	6
16	Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine). 1999 ·PubMed ·(unknown), Tadakazu Akiyama, Makiko Shimizu, Tatsuya Tamaoki, C Courage, Andreas J. Gescher, Shiro Akinaga	30
17	Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration 1999 ·Cancer Chemotherapy and Pharmacology ·Takeshi Takahashi, (unknown), Shiro Akinaga, Tatsuya Tamaoki, Masami Okabe	31
18	A Pure Antiestrogen, ICI 182,780, Stimulates the Growth of Tamoxifen-Resistant KPL-1 Human Breast Cancer Cells in vivo but not in vitro 1998 ·Oncology ·Junichi Kurebayashi, Takemi Otsuki, Shigeru Yamamoto, Masafumi Kurosumi, Taisuke Nakata, Shiro Akinaga, Hiroshi Sonoo	30
19	Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a and its mechanism of action 1992 ·Cancer Chemotherapy and Pharmacology ·Shiro Akinaga, Tadashi Ashizawa, Katsushige Gomi, (unknown), Makoto Morimoto, Chikara Murakata, Masami Okabe	23
20	Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. 1991 ·PubMed ·Shiro Akinaga, Katsushige Gomi, Makoto Morimoto, Tatsuya Tamaoki, Masami Okabe	167

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact